Loncastuximab tesirine

8月7日，必贝特涨9.12%，成交额2.23亿元，换手率12.68%，总市值114.17亿元。异动分析细胞免疫治疗+减肥药+创新药+科创次新股+注册制次新股1、根据招股说明书：截至本招股说明书签署日，国内已获批用于三线及以上治疗 r/r DLBCL 的药物为复星凯特引进的阿基仑赛注射液（Yescarta）、药明巨诺的瑞基奥仑赛注射液、罗氏制药的格菲妥单抗注射液（Columvi）、德琪医药引进的 Selinexor（塞利尼索片，XPOVIO，一种核输出抑制剂）、ADC Therapeutics 和瓴路药业联合申报的注射用替朗妥昔单抗、必贝特的BEBT-908（注射用盐酸伊吡诺司他）和上海恒润达生生物的雷尼基奥仑赛注射液，阿基仑赛注射液、瑞基奥仑赛注射液和雷尼基奥仑赛注射液均为 CAR-T 疗法。2、根据招股说明书：在研产品中，BEBT-808 是公司自主研发的一种口服小分子 GLP-1R 完全激动剂，用于治疗糖尿病和肥胖症，预计将于 2025 年提交临床试验申请。BEBT-809 是First-in-Class GPR75 通路抑制剂，用于治疗肥胖症，预计将于 2025 年提交临床试验申请。BEBT-701 为全球首个治疗高脂血症合并高血压的双靶点 siRNA 药物，预计将于 2025 年提交临床试验申请。3、广州必贝特医药股份有限公司主营业务是创新药物的研发、生产和销售。主要产品是小分子双靶点抑制剂。4、广州必贝特医药股份有限公司于2025-10-28上市，公司主营业务为创新药物的研发、生产和销售。5、广州必贝特医药股份有限公司于2025-10-28日上市，主营业务为创新药物的研发、生产和销售。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入74.62万，占比0%，行业排名89/157，连续2日被主力资金增仓；所属行业主力净流入42.64亿，当前无连续增减仓现象，主力趋势不明显。区间今日近3日近5日近10日近20日主力净流入74.62万-130.37万-799.97万532.87万8447.70万主力持仓主力没有控盘，筹码分布非常分散，主力成交额2345.70万，占总成交额的4.81%。技术面：筹码平均交易成本为25.61元该股筹码平均交易成本为25.61元，近期筹码关注程度减弱；目前股价在压力位28.21和支撑位20.70之间，可以做区间波段。公司简介资料显示，广州必贝特医药股份有限公司位于广东省广州市高新技术产业开发区科学城崖鹰石路25号A-3栋第七层、第八层，成立日期2012年1月19日，上市日期2025年10月28日，公司主营业务涉及创新药自主研发。必贝特所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗癌治癌、抗癌药物、细胞免疫治疗、基金重仓、减肥药等。截至7月20日，必贝特股东户数1.01万，较上期减少7.94%；人均流通股5270股，较上期增加8.62%。2026年1月-3月，必贝特实现营业收入0.00元；归母净利润-5273.57万元，同比减少45.49%。机构持仓方面，截止2026年3月31日，必贝特十大流通股东中，易方达医疗保健行业混合A（110023）位居第一大流通股东，持股212.76万股，相比上期增加141.99万股。博时天颐债券A（050023）位居第三大流通股东，持股112.42万股，为新进股东。长城消费增值混合A（200006）位居第七大流通股东，持股80.42万股，为新进股东。华宝生态中国混合A（000612）位居第八大流通股东，持股44.47万股，为新进股东。大摩健康产业混合A（002708）位居第九大流通股东，持股37.77万股，为新进股东。东方红医疗升级股票发起A（015052）、广发创新医疗两年持有期混合A（010731）、招商医药健康产业股票（000960）、交银医药创新股票A（004075）、广发沪港深医药混合A（014114）、东方红医疗创新混合(QDII)A（025070）、广发睿智两年持有期混合发起式A（013616）、招商前沿医疗保健股票A（011373）、融通中国风1号灵活配置混合A/B（001852）退出十大流通股东之列。

LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, August 13, 2026, at 8:30 a.m. EDT to report financial results for the second quarter of 2026 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl). ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: whether future LOTIS-7 results will be consistent with or different from the prior disclosure, the timing, results and publication of the full LOTIS-7 trial; the adequacy of the LOTIS-5 clinical trial data to support full regulatory approval and our ability to maintain accelerated approval in the United States and foreign jurisdictions for our product; the timing, content and outcome of meetings with and feedback or other communications provided by regulatory authorities including U.S. FDA; the timing, submission and acceptance of an sBLA submission related to LOTIS-5 and potential approval; the actual and perceived benefit-risk profile for ZYNLONTA® as studied in the LOTIS-5 trial; the assessment of the data from LOTIS-5 study, including additional analyses of outcomes observed for safety, efficacy and within key geographic regions and across certain patient sub-populations; the path for full regulatory approval for ZYNLONTA® in the United States and foreign jurisdictions; our ability to identify and execute value-maximizing options and the cost and impact of such options; our expected cash runway into at least 2028; our ability to comply with the terms of our indebtedness; changes in our regulatory and commercial strategy; the Company's ability to sustain or grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's clinical trials; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS: Investors and Media Nicole Riley ADC Therapeutics [email protected] +1 862-926-9040 SOURCE ADC Therapeutics SA 21% more press release views with Request a Demo